Clinical Trials
45 trialsSintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC
Sun Yat-sen University
SACTION 2501
Sun Yat-sen University
NIBCUN
Sun Yat-sen University
K-NADIR
The First Affiliated Hospital of Guangzhou Medical University
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
TJ Biopharma Co., Ltd.
CTONG 2508
Guangdong Association of Clinical Trials
STAR-SCLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
CCICC-002b
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study
Second Affiliated Hospital of Zunyi Medical University
Peri-E
Shanghai Chest Hospital
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
Tang-Du Hospital
Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
Shanghai Pulmonary Hospital, Shanghai, China
STAR
Peking Union Medical College Hospital
Example
Hunan Province Tumor Hospital
NEOTIDE
Guangdong Provincial People's Hospital
ACCLAIM
Shanghai Pulmonary Hospital, Shanghai, China
A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
Beijing Chest Hospital, Capital Medical University
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Neo-Pre-IC
The First Hospital of Jilin University
PRIORITY
Ningbo No.2 Hospital
JACKPOT33
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
Zhejiang Cancer Hospital
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
TRUMP
Guangdong Association of Clinical Trials
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
neoSCORE
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer
Peking Union Medical College Hospital
A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy
China Three Gorges University, Yichang, China
A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.
China Three Gorges University, Yichang, China
Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC
The First Affiliated Hospital with Nanjing Medical University
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
Zhejiang Cancer Hospital
A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC
China Medical University, China
Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study
Shanghai Cancer Hospital, China
Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer
Tianjin Medical University Second Hospital
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
Sichuan Cancer Hospital and Research Institute
Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer
Guangdong Association of Clinical Trials
Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer
Sun Yat-sen University
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
Zhejiang Cancer Hospital
Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)
Shanghai Chest Hospital
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
Fudan University
Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
Hunan Cancer Hospital
Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy
Peking Union Medical College
SMART
Tianjin Medical University Cancer Institute and Hospital
Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative
First Hospital of Shijiazhuang City